Vacc-Ct1 - Immunor-AS
Alternative Names: Vacc Ct1 - Immunor-ASLatest Information Update: 29 Mar 2024
At a glance
- Originator Immunor AS
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Glioblastoma
Most Recent Events
- 07 Feb 2024 Preclinical trials in Glioblastoma in Norway (Parenteral) (Immunor-AS Pipeline, February 2024)
- 07 Feb 2024 Immunor-AS plans a phase II trial for Glioblastoma (Parenteral) (Immunor-AS Pipeline, February 2024)